Belgian immune inflammation biotechnology company AgomAb Therapeutics (AGMB.US) applies for IPO in the United States, aiming to raise $100 million.

The clinical-stage biotechnology company AgomAb Therapeutics (AGMB.US), headquartered in Belgium and focused on the field of immunology and inflammatory diseases, submitted an application to the U.S. Securities and Exchange Commission (SEC) last Friday, planning to raise up to $100 million through an initial public offering (IPO). According to the prospectus, AgomAb Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing innovative disease-modifying therapies in the field of immunology and inflammatory diseases. The company's initial focus is on treating chronic fibrotic diseases with high unmet medical needs by inhibiting the key signaling pathway for fibrosis - the transforming growth factor (TGF) pathway. Its lead candidate drug, ontunisertib (AGMB-129), is a selective, potent oral gastrointestinal-restricted ALK5 (i.e. TGFR1) small molecule inhibitor currently being developed for the treatment of fibrostenotic Crohn's disease (FSCD). The second clinical-stage candidate drug, AGMB-447, is an inhaled ALK5 (i.e. TGFR1) small molecule inhibitor being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The company, based in Antwerp, Belgium, was founded in 2017 and plans to list on the NASDAQ under the stock ticker "AGMB". AgomAb Therapeutics had previously submitted a confidential IPO filing on June 20, 2024. The joint bookrunners for this IPO include J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen, with specific pricing terms yet to be disclosed.